- Scientific Programme
- Registration Fees
- Advisory – Unofficial Agencies
- Travel Grants
- Industry Services
- Industry Symposia
Tuesday, 17 September – Friday, 20 September 2019
Abstract Submission is now open and available via the MyEASD
platform. If you are a member of EASD or you have already an account
for the EASD Virtual Meeting or Annual Meeting registration, you can use
the login details from your existing account (email address and
password) to login to MyEASD and access the Abstract Submission System
for the 55th EASD Annual Meeting. All other users / abstract submitters
will need to create a MyEASD account to have access. The submission deadline is 1 April 2019.
Communications must be delivered in English. There is no simultaneous translation.
It is not permitted to take photographs and/or film during any of the sessions.
Receipt of Abstract
Abstracts can only be submitted online and MUST be submitted BEFORE 1 APRIL 2019 23:59 hrs CEST.
THIS DEADLINE WILL BE STRICTLY ENFORCED, as will be the regulations
given below. The EASD office will notify the presenting (= first named)
author when the abstracts with the status “complete” are forwarded for
Submission of Abstracts
The following is a brief overview of the abstract submission process. Please read carefully the DETAILED ABSTRACT SUBMISSION GUIDELINES before you begin the abstract submission process.
It is not permitted
to submit work that has been published and/or is likely to be published
before the EASD Abstract submission deadline (1 April 2019, 23:59 hrs.
CEST). The Programme Committee has the right to remove an abstract if
this contains data that has already been published. However, EASD
accepts the submission of abstracts that have been presented in recent
months at local or national diabetes meetings (e.g. ADA, DDG). An author
submitting or presenting work that has been published in a journal
before the EASD Abstract submission deadline (1 April 2019, 23:59hrs
CEST) will be banned from presenting data at the EASD Meetings for three
Abstracts submitted on Human Studies:
box must be marked stating that the study has been reviewed by the
Local Ethics Committee and that it has therefore been performed in
accordance with the ethical standards laid down in the Helsinki
Declaration (see World Medical Association: www.wma.net).
Abstracts submitted on Animal Studies:
box must be marked stating that the study has been carried out along
the “Principles of laboratory animal care” (NIH Publication no. 85-23,
revised 1985) and according to the national law, if applicable.
Selection of abstracts for the Scientific Programme is made anonymously. THE ABSTRACT MUST BE SUBMITTED as follows:
author can be listed ONLY ONCE as the PRESENTING author (presenting
author is always the first named author in the author block) on ONE (1)
abstract.Each additional abstract will be removed from the
system and will not be forwarded to the Review Committee. Additional
abstracts will not be reviewed. Presenting authors may be co-authors of
other abstracts. It is mandatory that the presenting author of
any abstract accepted for presentation attends the 55th EASD Annual
Meeting 2019 to present his / her paper. Failure to do so, without prior or adequate explanation sent to the EASD Office by e-mail, may result in the author or the institution being banned from presenting abstracts for the next three years.
are welcome from non-members of EASD. Please refer to the Registration
section of this General Information, regarding the date by which authors
must become members of EASD in order to qualify for preferential
registration fees. These regulations will be strictly enforced.
abstract must be submitted in English. New authors should create an
account using a login name and a password. With this information they
can revise the submission as often as required, make changes, additions,
amendments, change/add/delete authors, copy special characters easily
into the text, re-write the abstract or copy and paste the text in the
corresponding boxes. All this is possible until the Abstract Submission Deadline: 1 April 2019 23:59 hrs CEST. After this date the submission site will be closed. IMPORTANT!:
Always double check that the “complete” status of your submitted
abstract has NOT been affected after having edited it.
CHANGES TO THE CONTENT AND/OR THE AUTHOR BLOCK OF THE SUBMITTED ABSTRACT WILL NOT BE ACCEPTED after the submission deadline.
Your abstract submission must adhere the following structure:
- The maximum number of characters is 3,200 (excl. spaces) including the title and the author block. The title should be short (maximum 150 characters).
- Please enter your name and the names of co-authors as given in the example below. Start each name with a capital letter and continue in lower case, do not enter names/affiliations all in capital letters.
First Name: John
2nd Initial: J
3rd Initial: R
Last Name: Macleod
- The abstract must be structured. Enter each section into the corresponding text field with the provided sub-headings in bold (Background and aims:, Materials and methods:, Results: and Conclusion:).
The abstract structuring words are fixed for each abstract text box.
One or two sentences should describe the methods, and any aspects of
methodology (e.g. use of control groups, randomisation, patient
selection, assay variation). The sentences stating the results must
include hard data, including statistical analysis.
- It is allowed to include only one table OR one
graph to your abstract, but 400 characters will be deducted from the
maximum number of characters allowed. Tables must be uploaded as an
image; so you must create your table and convert it into an image in
order to include it in your abstract. You can edit your table or graph
and then replace it, or delete it until the submission deadline of 1
April 2019, 23:59 hrs CEST. Do not enter both (a table and a graph) in the same image file; also,
do not create and upload multi panel images. When creating a table, do
not to exceed a number of 10 columns and 12 rows with a maximum of 3
lines per row!
- References are not allowed.
- For drugs exclusively generic names should be used (no trademarks).
- A list of approved abbreviations and units of expression for use without definition appears in DIABETOLOGIA.
- Grant/Support information must be entered into its designated field.
- Where applicable, the Clinical Trial Registration Number must be entered into its designated field; not in the abstract body.
- Only one keyword can be selected.
- Abstracts CANNOT be submitted as an e-mail attachment.
- A signed copy of the final version of the abstract must be sent ONLY per e-mail as PDF file attachment to: email@example.com by 9 April 2019, 23:59 hrs CEST.
In case of questions, or if you have not received a reply by 15 April 2019, please call: +49-211-75 84 69 0 or contact firstname.lastname@example.org.